Insider Purchases: Inside the Buy
Tag: stock market
🏗️ AECOM (ACM): The $26 Billion Backlog Infrastructure Giant Trading at 12x Earnings
AECOM (NYSE: ACM) may be one of the most misunderstood infrastructure stocks in the market. With a record $26.2 billion backlog, insider buying from top executives, and a surprisingly cheap valuation, this engineering and consulting powerhouse could be quietly laying the foundation for substantial long-term upside.
🥚 Vital Farms (VITL): The Great Egg Glut of 2026
Vital Farms stock has been absolutely scrambled by the 2026 egg glut, plunging more than 80% from its highs as profitability collapsed and short sellers flooded the farm. But coordinated insider buying, a debt-free balance sheet, and extreme institutional ownership suggest the setup may be far more explosive than the market currently realizes.
🐟 Nomad Foods (NOMD): The Frozen Food Giant Trading Like a Distressed Stock
Nomad Foods may not be sexy, but Europe’s frozen-food empire is suddenly attracting serious insider buying, quant fund interest, and deep-value investors. With a near-7% dividend yield, aggressive buybacks, and a forward P/E near 5x, NOMD might be one of the market’s coldest contrarian opportunities.
Lululemon (LULU): 68% Off — Bargain or Value Trap? 🧘
Lululemon (LULU) has fallen sharply from its highs, but insider buying and international growth suggest opportunity. Is this a contrarian buy—or a value trap in disguise?
Is Boeing Ready to Fly?
Boeing’s new director — ex-Vanguard CEO Tim Buckley — just bought nearly $500K of stock. With a $619B backlog and cash flow stabilizing, is this aerospace giant finally ready for liftoff… or more turbulence?
iHeartMedia (IHRT): Turning the Volume Back Up?
Insiders are piling in, institutions are holding strong, and iHeartMedia is betting big on podcasts to fuel its turnaround. But with heavy debt and radio stagnation, is IHRT a hidden gem or just background noise?
Eastman Kodak (KODK): Insider Buys, Debt Drama & a Pivot to Pills?!
Eastman Kodak insiders are snapping up shares, with CEO Jim Continenza leading the charge. But Kodak’s finances are shaky, its debt heavy, and its pivot to pharmaceuticals uncertain. High risk, high reward — or just a faded picture?
Figma (FIG): Directors Buy In — Should You Collaborate?
🎨 Figma stock exploded out of the IPO gate, hitting highs nearly 5x insider purchase prices. With no profits, big Bitcoin bets, and stiff competition, is this design darling still worth the hype? Let’s sketch it out—icons, jokes, and all.
Progress Software CEO Buys In — Maybe It’s More Than Just... Progress?
Progress Software's CEO and a director are buying shares, signaling confidence as the company posts strong earnings and raises guidance. With institutional investors owning over 121% of the float, is this under-the-radar compounder set for a rerating?
Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”
Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?